Daniel M Halperin, MD
Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine
About Dr. Halperin
Dr. Halperin is a medical oncologist and clinical investigator focused on the development of novel treatments for patients with neuroendocrine tumors (NETs), in addition to providing high-quality clinical care to patients with NETs and other gastrointestinal cancers. He leads clinical trials of new drugs for patients with NETs at MD Anderson, and works together with a team of laboratory and population scientists to understand more fully the molecular underpinnings and clinical manifestations of neuroendocrine tumors. He is also a member of the Neuroendocrine and Adrenal Tumor guideline committee of the National Comprehensive Cancer Network, contributing to evidence-based guidelines for the care of NET patients. Dr. Halperin has a particular interest in the immunology of neuroendocrine tumors and the use of immunotherapy for patients with NETs. As such, he has received peer-reviewed funding from the Neuroendocrine Tumor Research Foundation, as well as a Career Development Award from the American Society of Clinical Oncology, to understand the immunology of NETs and leads a clinical trial of immunotherapy with atezolizumab and bevacizumab for patients with specific rare solid tumors, including two separate cohorts of patients with advanced well-differentiated NETs.
Ongoing clinical trials include:1. A Phase II, Single-Arm Open-Label Study of the Combination Of Atezolizumab and Bevacizumab in Rare Solid Tumors (NCT03074513).
2. PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers (NCT02936323).
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2009 | Weill Cornell Medical College, New York, NY, USA, MD, Medicine |
| 2004 | Massachusetts Institute of Technology, Cambridge, MA, USA, BS, Biology |
Postgraduate Training
| 2012-2015 | Clinical Fellowship, Medical Oncology, MD Anderson Cancer Center, Houston, TX |
| 2009-2012 | Clinical Residency, Internal Medicine, Brigham and Women's Hospital, Boston, MA |
Board Certifications
| 2015 | ABIM: Medical Oncology |
| 2013 | ABIM: Internal Medicine |
Experience & Service
Academic Appointments
Clinical Fellow, Division of Internal Medicine, Harvard Medical School, Boston, MA, 2009 - 2012
Other Appointments/Responsibilities
Member, MD Anderson Rare Tumor Working Group, Houston, TX, 2016 - Present
Institutional Committee Activities
Member, Investigational New Drug Committee, 2020 - Present
Chair, Neuroendocrine Tumor Multidisciplinary Conference, 2020 - Present
Member, Clinical Research Committee, 2018 - Present
Honors & Awards
| 2018 | American Society of Clinical Oncology Career Development Award |
| 2015 | Waun Ki Hong Award for Clinical Investigation, MD Anderson Cancer Center |
| 2014 | Resident Recognition Award, Harvard Medical School |
| 2012 | Novartis Advanced Scholar in Neuroendocrine Tumors, MD Anderson Cancer Center |
| 2009 | Coryell Prize, Weill Cornell Medical College |
| 2008 | Alpha Omega Alpha Honor Medical Society |
| 2006 | Research Training Fellowship for Medical Students, Howard Hughes Medical Institute |
| 2002 | Research Experience for Undergraduates Scholarship, National Science Foundation |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Hernandez Vargas S, Lin C, Voss J, Ghosh SC, Halperin DM, AghaAmiri S, Cao HST, Ikoma N, Uselmann AJ, Azhdarinia A. Development of a drug-device combination for fluorescence-guided surgery in neuroendocrine tumors. J Biomed Opt 25(12), 2020. PMID: 33300316.
- Eads JR, Reidy-Lagunes D, Soares HP, Chan JA, Anthony LB, Halfdanarson TR, Naraev BG, Wolin EM, Halperin DM, Li D, Pommier RF, Zacks JS, Morse MA, Metz DC, from the Carcinoid Syndrome Control Collaborative. Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors. Pancreas 49(9):1123-1130, 2020. PMID: 32991344.
- Tang T, Abu-Sbeih H, Ma W, Lu Y, Luo W, Foo WC, Richards DM, Halperin DM, Ge PS, Wang Y. Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy. Clin Colorectal Cancer 19(3):e117-e123, 2020. e-Pub 2020. PMID: 32284253.
- Pieterman CRC, Sadowski SM, Maxwell JE, Katz MHG, Lines KE, Heaphy CM, Tirosh A, Blau JE, Perrier ND, Lewis MA, Metzcar JP, Halperin DM, Thakker RV, Valk GD. MEN1-related PanNETs: identifying unmet clinical needs and future directives. Endocr Relat Cancer 27(8):T9-T25, 2020. e-Pub 2020. PMID: 32069215.
- Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, O'Dorisio TM, Halperin DM, Fishbein L, Eads J, Hope TA, Singh S, Salem R, Metz DC, Naraev BG, Reidy-Lagunes DL, Howe JR, Pommier RF, Menda Y, Chan JA. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Pancreas 49(7):863-881, 2020. PMID: 32675783.
- Bergsland EK, Halperin DM, Dillon JS, Dasari NA, Kunz PL, Soares HP, Pryma D, Bodei L, Hope T, Soulen MC, Mailman J, Howe JR. North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19. Pancreas 49(6):723-728, 2020. PMID: 32433264.
- Vijayvergia N, Dasari A, Deng M, Litwin S, Al-Toubah T, Alpaugh RK, Dotan E, Hall MJ, Ross NM, Runyen MM, Denlinger CS, Halperin DM, Cohen SJ, Engstrom PF, Strosberg JR. Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials. Br J Cancer 122(9):1309-1314, 2020. e-Pub 2020. PMID: 32152503.
- Abu-Sbeih H, Mallepally N, Goldstein R, Chen E, Tang T, Dike UK, Al-Asadi M, Westin S, Halperin D, Wang Y. Gastrointestinal toxic effects in patients with cancer receiving platinum-based therapy. J Cancer 11(11):3144-3150, 2020. e-Pub 2020. PMID: 32231718.
- Dasari A, Joish VN, Perez-Olle R, Dharba S, Balaji K, Halperin DM. Direct costs of carcinoid syndrome diarrhea among adults in the United States. World J Gastroenterol 25(47):6857-6865, 2019. PMID: 31885426.
- Shen C, Dasari A, Chu Y, Halperin DM, Zhou S, Xu Y, Shih YT, Yao JC. Clinical, pathological, and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors. Ann Oncol 30(11):1847, 2019. PMID: 31407007.
- Shen C, Gu D, Zhou S, Xu Y, Sarshekeh AM, Halperin D, Shih YT, Yao JC, Dasari A. Racial Differences in the Incidence and Survival of Patients With Neuroendocrine Tumors. Pancreas 48(10):1373-1379, 2019. PMID: 31688604.
- Naraev BG, Halland M, Halperin DM, Purvis AJ, O'Dorisio TM, Halfdanarson TR. Management of Diarrhea in Patients With Carcinoid Syndrome. Pancreas 48(8):961-972, 2019. PMID: 31425482.
- Balanescu DV, Donisan T, Lopez-Mattei J, Hassan S, Kim P, Dasari A, Halperin D, Yao J, Kar B, Gregoric I, Balanescu SM, Iliescu C. The 1, 2, 3, 4 of carcinoid heart disease: Comprehensive cardiovascular imaging is the mainstay of complex surgical treatment. Oncol Lett 17(5):4126-4132, 2019. e-Pub 2018. PMID: 30944605.
- Samdani RT, Wasylishen AR, Halperin DM, Dasari A, Yao JC, Rashid A, Estrella JS. Loss of Menin Expression by Immunohistochemistry in Pancreatic Neuroendocrine Tumors: Comparison Between Primary and Metastatic Tumors. Pancreas 48(4):510-513, 2019. e-Pub 2019. PMID: 30946241.
- Halperin DM, Lee JJ, Ng CS, Strosberg JR, Estrella JS, Dagohoy CG, Dasari A, Yao JC. A Phase II Trial of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors. Pancreas 48(3):381-386, 2019. e-Pub 2019. PMID: 30768575.
- Halperin DM, Huynh L, Beaumont JL, Cai B, Bhak RH, Narkhede S, Totev T, Duh MS, Neary MP, Cella D. Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome. BMC Cancer 19(1):274, 2019. e-Pub 2019. PMID: 30922252.
- Serpas VJ, Raghav KP, Halperin DM, Yao J, Overman MJ. Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology. BMC Med Res Methodol 18(1):169, 2018. e-Pub 2018. PMID: 30541475.
- Halperin DM, Huynh L, Beaumont JL, Cai B, Totev T, Bhak RH, Duh MS, Neary MP, Cella D. Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: A survey study. Medicine (Baltimore) 97(47):e13390, 2018. PMID: 30461659.
- Shen C, Dasari A, Xu Y, Zhou S, Gu D, Chu Y, Halperin DM, Shih YT, Yao JC. Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors: A SEER-Medicare Database Study. Sci Rep 8(1):16863, 2018. e-Pub 2018. PMID: 30442902.
- Shen C, Dasari A, Gu D, Chu Y, Zhou S, Xu Y, Halperin D, Fu S, Yao JC, Shih YT. Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors. Pharmacoeconomics 36(8):1005-1013, 2018. e-Pub 2018. PMID: 29682693.
- Cloyd JM, Omichi K, Mizuno T, Kawaguchi Y, Tzeng CD, Conrad C, Chun YS, Aloia TA, Katz MHG, Lee JE, Halperin D, Yao J, Vauthey JN, Dasari A. Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases. Ann Surg Oncol 25(6):1709-1715, 2018. e-Pub 2018. PMID: 29626307.
- Shen C, Chu Y, Halperin DM, Dasari A, Zhou S, Xu Y, Yao JC, Shih YT. Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients. Oncologist 22(12):1451-1462, 2017. e-Pub 2017. PMID: 28642335.
- Sarshekeh AM, Advani S, Halperin DM, Conrad C, Shen C, Yao JC, Dasari A. Regional lymph node involvement and outcomes in appendiceal neuroendocrine tumors: a SEER database analysis. Oncotarget 8(59):99541-99551, 2017. e-Pub 2017. PMID: 29245922.
- Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 3(10):1335-1342, 2017. e-Pub 2017. PMID: 28448665.
- Nejati R, Goldstein JB, Halperin DM, Wang H, Hejazi N, Rashid A, Katz MH, Lee JE, Fleming JB, Rodriguez-Canales J, Blando J, Wistuba II, Maitra A, Wolff RA, Varadhachary GR, Wang H. Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy. Pancreas 46(9):1180-1187, 2017. PMID: 28902789.
- Shen C, Dasari A, Chu Y, Halperin DM, Zhou S, Xu Y, Shih YT, Yao JC. Clinical, pathological and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors. Ann Oncol 28(7):1582-1589, 2017. e-Pub 2017. PMID: 28444105.
- Qiu W, Christakis I, Stewart AA, Vodopivec DM, Silva-Figueroa A, Chen H, Woodard TL, Halperin DM, Lee JE, Yao JC, Perrier ND. Is estrogen exposure a protective factor for pancreatic neuroendocrine tumors in female multiple endocrine neoplasia syndrome type 1 patients?. Clin Endocrinol (Oxf) 86(6):791-797, 2017. e-Pub 2017. PMID: 28273369.
- Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, Shih YT, Yao JC. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol 18(4):525-534, 2017. e-Pub 2017. PMID: 28238592.
- Prakash L, Bhosale P, Cloyd J, Kim M, Parker N, Yao J, Dasari A, Halperin D, Aloia T, Lee JE, Vauthey JN, Fleming JB, Katz MH. Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. J Gastrointest Surg 21(1):155-163, 2017. e-Pub 2016. PMID: 27634306.
- Halperin DM, Lee JJ, Dagohoy CG, Yao JC. Rational Clinical Experiment: Assessing Prior Probability and its Impact on the Success of Phase II Clinical Trials. J Clin Oncol 33(26):2914-9, 2015. e-Pub 2015. PMID: 26261263.
- Phan AT, Halperin DM, Chan JA, Fogelman DR, Hess KR, Malinowski P, Regan E, Ng CS, Yao JC, Kulke MH. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol 16(6):695-703, 2015. e-Pub 2015. PMID: 25956795.
- Dasari A, Phan A, Gupta S, Rashid A, Yeung SC, Hess K, Chen H, Tarco E, Chen H, Wei C, Anh-Do K, Halperin D, Meric-Bernstam F, Yao J. Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors. Endocr Relat Cancer 22(3):431-41, 2015. e-Pub 2015. PMID: 25900182.
- Halperin DM, Phan AT, Hoff AO, Aaron M, Yao JC, Hoff PM. A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers. BMC Cancer 14:561, 2014. e-Pub 2014. PMID: 25086465.
- Ulloa L, Ochani M, Yang H, Tanovic M, Halperin D, Yang R, Czura CJ, Fink MP, Tracey KJ. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A 99(19):12351-6, 2002. e-Pub 2002. PMID: 12209006.
- Saleh M, Bhosale PR, Yano M, Itani M, Elsayes AK, Halperin D, Bergsland EK, Morani AC. New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms. Abdom Radiol (NY). e-Pub 2020. PMID: 33095312.
- Shaunfield S, Webster KA, Kaiser K, Greene GJ, Yount SE, Lacson L, Benson AB, Halperin DM, Yao JC, Singh S, Feuilly M, Marteau F, Cella D. Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index (FACT-CSI). Neuroendocrinology. e-Pub 2020. PMID: 32911478.
- Grubbs EG, Halperin DM, Waguespack SG, Gagel RF. History of the multiple endocrine neoplasia workshops and overview of MEN2019. Endocr Relat Cancer. e-Pub 2020. PMID: 32508314.
- Dasari A, Joish VN, Perez-Olle R, Dharba S, Balaji K, Halperin DM. Work productivity burden and indirect costs associated with carcinoid syndrome diarrhea. Expert Rev Pharmacoecon Outcomes Res:1-5. e-Pub 2019. PMID: 31448649.
Invited Articles
- Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. J Natl Compr Canc Netw 16(6):693-702, 2018. PMID: 29891520.
- Halperin DM, Dasari A, Yao JC. Future Directions in the Biology of Neuroendocrine Tumors. Pancreas 45(6):783-5, 2016. PMID: 27295529.
- Mehrvarz Sarshekeh A, Halperin DM, Dasari A. Update on management of midgut neuroendocrine tumors. Int J Endocr Oncol 3(2):175-189, 2016. e-Pub 2016. PMID: 27347369.
- Halperin DM, Yao JC. Clinical trial design in neuroendocrine tumors. Hematol Oncol Clin North Am 30(1):209-17, 2016. PMID: 26614378.
- Halperin DM, Kulke MH, Yao JC. A tale of two tumors: treating pancreatic and extrapancreatic neuroendocrine tumors. Annu Rev Med 66:1-16, 2015. e-Pub 2014. PMID: 25341008.
- Halperin DM, Varadhachary GR. Resectable, borderline resectable, and locally advanced pancreatic cancer: what does it matter?. Curr Oncol Rep 16(2):366, 2014. PMID: 24445498.
- Halperin DM, Kulke MH. Management of pancreatic neuroendocrine tumors. Gastroenterol Clin North Am 41(1):119-31, 2012. PMID: 22341253.
- Halperin DM, Dasari A, Yao JC. [(177)Lu-DOTA(0),Tyr(3)]-octreotate in the treatment of midgut neuroendocrine tumors. Future Oncol. e-Pub 2016. PMID: 26759064.
Editorials
- Halperin DM, Yao JC, Dasari A. What's in a Name? Steady Progress in Staging Pancreatic Neuroendocrine Tumors. J Clin Oncol 35(3):JCO2016707364, 2017. PMID: 27893328.
Book Chapters
- Halperin DM, Yao JC. Neuroendocrine Tumors. In: The MD Anderson Manual of Medical Oncology. 3. McGraw-Hill: China, 537-551, 2016.
Letters to the Editor
- Halperin DM, Shen C, Yao JC. Incidence and prognosis of carcinoid syndrome: hormones or tumour burden? - Authors' reply. Lancet Oncol 18: e300, 2017.
Grant & Contract Support
| Title: | Multidimensional Immune Profiling of Advanced Pancreatic Neuroendocrine Tumors |
| Funding Source: | Neuroendocrine Tumor Research Foundation |
| Role: | Principal Investigator |
| Title: | Harnessing the Immune System in Neuroendocrine Tumors |
| Funding Source: | American Society of Clinical Oncology (ASCO) |
| Role: | Principal Investigator |
| Title: | Chromogranin A as Surveillance biomarker |
| Funding Source: | BRAHMS GmbH |
| Role: | Principal Investigator |
| Title: | Tumor-Specific Delivery of Temozolomide to Overcome Resistance in GEP-NETS |
| Funding Source: | American Association for Cancer Research (AACR) |
| Role: | Collaborator |
| Title: | CCSG supplement: Creating an efficient clinical trial build system via the Clinical Trials Rapid Activation Consortium (CTRAC) |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |